# Meletios A. Dimopoulos

Source: https://onco.cc/people/meletios-dimopoulos/  
OnCo record `meletios-dimopoulos` (Person). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Greek haematologist who led POLLUX and CANDOR, two of the pivotal daratumumab combination trials in relapsed myeloma.

## Summary

Meletios Dimopoulos (University of Athens) was principal investigator of POLLUX, which established daratumumab plus lenalidomide-dexamethasone in relapsed myeloma, and CANDOR (daratumumab plus carfilzomib), and co-led APOLLO and the ELOQUENT trials. He has authored the IMWG guidelines on renal impairment in myeloma and led the international consensus on Waldenström macroglobulinaemia treatment.

## Fields

- Kind: Person
- Last checked: 2026-09-10
- Tags: myeloma; trialist; greece
- Role: Professor of Hematology and Medical Oncology, National and Kapodistrian University of Athens
- Specialisms: Multiple myeloma; Waldenström macroglobulinaemia; Daratumumab and carfilzomib combinations; Renal impairment

## Sources

- PubMed: https://pubmed.ncbi.nlm.nih.gov/?term=Dimopoulos%20MA%5BAuthor%5D%20myeloma%20daratumumab

## Connected records

- cancers: [Multiple myeloma](https://onco.cc/cancers/multiple-myeloma/), [Waldenström macroglobulinaemia](https://onco.cc/cancers/waldenstrom/)
- technologies: [Monoclonal antibodies](https://onco.cc/technologies/monoclonal-antibody/)
- targets: [CD38](https://onco.cc/targets/cd38/)
- institutions: [National and Kapodistrian University of Athens, School of Medicine](https://onco.cc/institutions/nkua-athens/)
- trials: [AQUILA](https://onco.cc/trials/aquila/)

---
JSON: https://onco.cc/api/v1/entities/meletios-dimopoulos.json